Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin for recurrent grade II or III meningioma
NL-OMON44858Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trabectedin in meningioma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Nov 2015; status: active, not recruiting.
02
Drugs
trabectedin
03
Conditions
meningioma
Beyond the preview
Go deeper on NL-OMON44858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44858.